GrantExec

Grants for Public housing authorities - Education

Explore 751 grant opportunities

Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U01 Clinical Trial Not Allowed)
$4,000,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 7, 2024

Date Added

Jul 19, 2024

This grant provides funding for research teams to study how early-life social and environmental factors influence brain development and addiction risk using animal models and advanced neuroscience techniques.

Education
State governments
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
$275,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Oct 15, 2024

Date Added

Nov 1, 2023

The National Cancer Institute is offering funding for research projects aimed at validating the effectiveness of various markers and assays in cancer detection, diagnosis, treatment, and prevention, with a focus on developing these into clinical assays and ensuring their performance across multiple laboratories.

Education
State governments
Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trials Optional)
$350,000
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

Jul 17, 2024

Date Added

Feb 21, 2024

This notice of funding opportunity (NOFO) will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels. Research on substance use disorders (SUDs) has primarily focused on individual substances although polysubstance use is prevalent. Polysubstance use is the use of more than one addictive substance within a defined interval; the use may be sequential (use of multiple substances on separate occasions), or concurrent/simultaneous. Limiting studies to an individual addictive substance overlooks potential interactions between substances and could influence the translational potential of preclinical research findings. Results from several studies have demonstrated that the use of multiple addictive substances produces pharmacokinetic and behavioral profiles that are distinct from those produced by a single substance. Despite this recognition, little is known about the precise pharmacological mechanisms and interactions that may contribute to such outcomes, or co-morbidities resulting from co-use. There is also a significant lack in our understanding of how the activity of discrete cells, genes, circuits, expression of receptors, ion channels, intrinsic excitability or signaling mechanisms in the reward systems synergize when exposed to distinct classes of drugs simultaneously or sequentially. Even less is known about these mechanisms in brain regions and circuits that underlie negative reinforcement, or how neurotransmitters, neuromodulators or stress interact within these circuits to contribute to the behavioral and pharmacological profiles observed following polysubstance use. In addition, there is a need for behavioral models of polysubstance use that have translational potential. Research Objectives: The National Institute on Drug Abuse (NIDA) seeks to stimulate innovative research that will transform our understanding of the basic mechanisms that underlie polysubstance use in addiction. These studies will investigate novel neurobiological, pharmacological and/or behavioral mechanisms underlying the biobehavioral outcomes of polysubstance use. Research areas and questions of programmatic interest include, but are not limited to: Identification and/or characterization of molecules, genes, cells (including non-neuronal cells), neural pathways, circuits, receptors, ion channels, intrinsic excitability, pharmacological and signaling mechanisms mediating the effects of polysubstance use. Mechanisms underlying the association of early adolescent polysubstance use with SUDโ€™s in adulthood. Sex differences in the development and trajectory of polysubstance use. What are the roles of organizational and activational effects of sex steroids on discrete brain regions and neural circuits, and how is this altered with exposure to polysubstance use? What are the developmental determinants? Are there developmental windows during which polysubstance use would be facilitated? What are the pharmacologic, pharmacokinetic and pharmacodynamic interactions that can impact toxicity, or the SUD trajectory? How do environmental factors interact with brain circuits to influence the development and trajectory of SUDs involving polysubstance use? How does stress interact with brain circuits to influence the development and trajectory of SUDs involving polysubstance use? Are there neurobehavioral risk phenotypes for progression to polysubstance use? What are the neurocognitive and neurobehavioral changes that occur through experience with different patterns of polysubstance use? Applications Not Responsive to this Notice of Funding Opportunity (NOFO) The following types of studies are not responsive to this NOFO and will not be reviewed: The major goal of the project is not targeted at delineating the basic mechanisms underlying polysubstance use in addiction. Projects limited exclusively to the phenomenology of polysubstance use, consequences of polysubstance use, or those focused exclusively on the development of tools or animal models. Projects that do not focus on combinations of two or more addictive substances with well-justified translational and public health relevance. Projects that do not include a psychostimulant, opioid, or cannabinoid in the polysubstance combination. Alcohol may be included in the polysubstance combination. Research that does not pertain to at least one of the stages of the substance use trajectory, including, but not limited to initiation, escalation, withdrawal and/or relapse. Other application considerations: Collaborative research teams to foster the sharing of conceptual and/or technical expertise are strongly encouraged. Applicants using animal models are encouraged to use models reflective of chronic and voluntary drug intake. Preliminary data are not required but may be included if available. In the absence of preliminary data, a strong premise should be provided for testing a novel hypothesis based upon the scientific literature as well as evidence of the teamโ€™s ability to carry out the proposed studies through published or technical preliminary data.

Education
State governments
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
$250,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 5, 2024

Date Added

Jan 18, 2024

This funding opportunity supports early-stage researchers in cancer control and population sciences to explore innovative ideas that can significantly advance cancer research and improve healthcare delivery.

Education
State governments
Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed)
$300,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Oct 29, 2024

Date Added

Jun 21, 2024

This funding opportunity supports researchers conducting basic science studies to explore how sleep and circadian rhythms are connected to substance use disorders, aiming to improve understanding and treatment of these issues.

Education
State governments
Community Impact Grants
$50,000
Greater Toledo Community Foundation
Private

Application Deadline

Not specified

Date Added

Dec 9, 2024

This grant provides funding to nonprofit organizations in northwest Ohio and southeast Michigan for innovative programs that improve community well-being, focusing on safety, family support, and youth development.

Community Development
Nonprofits
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
$2,000,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 13, 2024

Date Added

Mar 15, 2024

This grant provides funding for researchers to explore the complex interactions between the brain and immune system in the context of HIV and substance use disorders, aiming to identify new therapeutic targets and improve understanding of related neurological issues.

Education
State governments
BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)
$3,000,000
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

May 8, 2024

Date Added

Jan 21, 2022

Reissue of RFA-MH-20-128 This Funding Opportunity Announcement (FOA) solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will cover the way that all of those groups are collecting data. The developed standard is expected to be made widely available.

Education
State governments
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
$200,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 8, 2024

Date Added

Feb 18, 2022

This funding opportunity supports researchers exploring the use of microorganisms, like bacteria and viruses, to develop innovative methods for cancer imaging, diagnosis, and treatment.

Education
State governments
BRAIN Initiative: Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 4, 2024

Date Added

Mar 21, 2024

This funding opportunity supports researchers in developing and testing innovative devices for diagnosing and treating disorders of the nervous system through small clinical studies and safety assessments.

Education
State governments
Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
$275,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Oct 30, 2024

Date Added

Nov 21, 2022

This grant provides funding for researchers to explore how diet and lipid metabolism influence tumor growth and progression, encouraging innovative studies that connect nutrition science with cancer biology.

Education
State governments
NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
$50,000
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Jan 7, 2025

Date Added

Dec 5, 2022

This grant provides funding for small-scale cancer research projects that can be completed in two years, aimed at supporting innovative studies and methodologies in various areas of cancer research.

Education
State governments
Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Feb 24, 2025

Date Added

Nov 30, 2023

This funding opportunity supports researchers working to identify and address health and healthcare disparities affecting sexual and gender minority populations, particularly those from racial/ethnic minority and lower socioeconomic backgrounds.

Education
State governments
INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed)
$275,000
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

Jul 1, 2024

Date Added

Apr 5, 2022

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in Down syndrome. This initiative seeks applications that are intended to facilitate Down syndrome research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials for Down syndrome and its co-occurring conditions, and to increase their likelihood of success through development and testing of biomarkers and clinical outcome assessment measures, development and testing of novel trial methods and recruitment strategies, or by defining the presentation and course of the co-occurring conditions in individuals with Down syndrome to enable the design of future clinical trials.

Education
State governments
NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
Contact for amount
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 4, 2025

Date Added

Aug 23, 2024

This funding opportunity provides financial support to exceptional clinician scientists who contribute to the development and implementation of NCI clinical trials, ensuring their continued involvement in cancer research without being principal investigators on research project grants.

Education
State governments
Advancing Research on Molecular Targets and Mechanisms that Influence the Interplay Between Sex Hormones, HIV, and Addictive Substances (R01 Clinical Trials Not Allowed)
$400,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Mar 13, 2025

Date Added

Aug 16, 2024

This grant provides funding for research projects that explore how sex hormones affect HIV progression and substance use disorders, aiming to develop new therapeutic strategies for these interconnected health issues.

Education
State governments
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
Contact for amount
U.S. Department of Health and Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 19, 2024

Date Added

Apr 19, 2023

This funding opportunity supports research projects that develop and test innovative strategies to improve cancer screening and preventive services for populations facing health disparities, such as racial and ethnic minorities, low-income groups, and rural communities.

Education
State governments
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
$600,000
HHS-NIH11 (National Institutes of Health)
Federal

Application Deadline

Jun 11, 2024

Date Added

Sep 16, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying those patients at high risk of PDAC (because of genetic factors or presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens and data within the Consortium. The other scientific component of the PCDC will be the Management and Data Coordination Unit (MDCU). The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort. The PCDC-MDCU will also supp

Education
State governments
Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
$500,000
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 19, 2024

Date Added

Nov 6, 2023

This funding opportunity provides financial support for researchers to explore innovative ways to integrate genomic information into clinical care, particularly focusing on diverse and underserved populations to improve health equity.

Education
State governments
Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
Contact for amount
U.S. Department of Health & Human Services (National Institutes of Health)
Federal

Application Deadline

Nov 25, 2024

Date Added

Jul 19, 2023

This grant provides funding for researchers to explore how HIV and substance use disorders affect protein interactions in microglia, aiming to uncover mechanisms that could lead to new treatments for these interconnected conditions.

Education
State governments